J Korean Ophthalmol Soc > Volume 50(2); 2009 > Article
Journal of the Korean Ophthalmological Society 2009;50(2):219-226.
DOI: https://doi.org/10.3341/jkos.2009.50.2.219    Published online February 15, 2009.
Short-term Safety and Efficacy of Intravitreal Bavacizumab Injection.
Su Jin Kim, Young Min Park, Seung Uk Lee, Ji Eun Lee, Boo Sup Oum
Department of Ophthalmology, College of Medicine, Pusan National University, Pusan, Korea. jlee@pusan.ac.kr
유리체강속 베바시주맙 주사의 단기간 안전성 및 효용성
김수진ㆍ박영민ㆍ이승욱ㆍ이지은ㆍ엄부섭
Department of Ophthalmology, College of Medicine, Pusan National University, Pusan, korea
Abstract
PURPOSE
To evaluate the short-term safety and efficacy of intravitreal bevacizumab (Avastin(R)) injection for various conditions. METHODS: The medical records of 257 eyes of 251 patients who underwent intravitreal bevacizumab injections were reviewed. Central retinal thickness on optical coherence tomography and visual acuity before injections, at 1 week, 1 month, 2 months and 3 months after injections were analyzed. RESULTS: The patients included age-related macular degeneration (89 eyes), diabetic macular edema (67 eyes) and retinal vascular occlusion (57 eyes). The number of injections was twice in 82 eyes, 3 times in 23 eyes and 4 times in 2 eyes. In total, 391 injections were performed. Best corrected visual acuity increased significantly at 3 months (p=0.033) and central retinal thickness decreased by 1 month and was maintained until 3 months after the first injection (p<0.001). No serious drug-related ocular or systemic adverse incidents including endophthalmitis, glaucoma, retinal detachment, hypertension or myocardial infarction were identified. CONCLUSIONS: The intravitreal bevacizumab injection was safe and efficient for macular edema in this short-term study.
Key Words: Bevacizumab;Efficacy;Safety


ABOUT
BROWSE ARTICLES
EDITORIAL POLICY
FOR CONTRIBUTORS
Editorial Office
SKY 1004 Building #701
50-1 Jungnim-ro, Jung-gu, Seoul 04508, Korea
Tel: +82-2-583-6520    Fax: +82-2-583-6521    E-mail: kos08@ophthalmology.org                

Copyright © 2021 by Korean Ophthalmological Society.

Developed in M2PI

Close layer
prev next